Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Chinese Adults with Transfusion-Dependent Beta-Thalassemia
NCT05567458Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Primary completion
- Aug 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in beta thalassemia comparing Luspatercept Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of participants with ≥ 33% reduction from baseline in red blood cell (RBC) transfusion burden over any consecutive 24 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT05567458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567458.